The trademark application THERIVA was filed by Theriva Biologics, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on August 7, 2022, and it was registered by office on November 14, 2022 without any oppositions.
The application was filed in English (French was selected as the second language).
A transfer of the trademark registration was recorded on February 15, 2023. A transfer of the trademark registration was recorded on April 12, 2023. Change of name and address of the trademark registration was recorded on May 4, 2023.
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations for the treatment, prevention and alleviation of gastrointestinal diseases, infections, dysbiosis, and disorders
Pharmaceutical preparations for the treatment of metabolic diseases and disorders
Pharmaceuticals, namely, pharmaceutical preparations for gastrointestinal health, used to maintain health and restore health to a human or animal subject via treatment of a disturbed microbial community and prevention of microbial community disruption
Pharmaceuticals, namely, pharmaceutical preparations for gastrointestinal dysbiosis and systemic illnesses associated with gastrointestinal dysbiosis, used to maintain health and restore health to a human or animal subject via treatment of a disturbed microbial community and prevention of microbial community disruption
Pharmaceuticals, namely, pharmaceutical preparations for gastrointestinal disorders and systemic illnesses associated with gastrointestinal disorders, used to maintain health and restore health to a human or animal subject via treatment of a disturbed microbial community and prevention of microbial community disruption
Pharmaceuticals, namely, pharmaceutical preparations for gastrointestinal diseases and systemic illnesses associated with gastrointestinal diseases, used to maintain health and restore health to a human or animal subject via treatment of a disturbed microbial community and prevention of microbial community disruption
Pharmaceuticals, namely, pharmaceutical preparations for gastrointestinal infections and systemic illnesses associated with gastrointestinal infections, used to maintain health and restore health to a human or animal subject via treatment of a disturbed microbial community and prevention of microbial community disruption
Pharmaceutical preparations, namely, preparations for use in the treatment of cancer and tumors
Oncolytic viral therapies
Biological therapies for use in the treatment of cancer and tumors.